Ipsen signs $1.8bn RNA drug alliance with Skyhawk
Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023...
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article...
Ipsen Inks Potential $900M Deal with Sutro for Global Rights to Preclinical ADC
Merrimack Receives $225 Million Milestone Payment from Ipsen
Ipsen`s Biologic Increlex (mecasermin) Receives Approval in the U.S.
Ipsen - Monthly information relative to the total number of voting rights
Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements ...
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS...